ObsEva – $97 Million IPO

New York – February 16, 2017 – Cooley advised ObsEva on its $96.8 million initial public offering of 6,450,000 common shares. The underwriters maintain a 30-day option to purchase up to 967,500 additional common shares. The company now trades on the NASDAQ Global Select Market as “OBSV.”

ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Div Gupta Partner, New York
Nicole Brookshire Partner, Boston
Charlie Kim Partner, San Diego
Mark Ballantyne Associate, Reston
Esther Cho Associate, Boston
Natasha Leskovsek Partner, Washington, DC
Phil Mitchell Partner, New York
Bill Christiansen Partner, Seattle
Barbara Mirza Partner, Los Angeles
John McKenna Partner, Palo Alto
Paula Holland Partner, London
Helenanne Connolly Special Counsel, Reston
Geoffrey Spolyar Special Counsel, Boston
Aaron Nudelman Associate, Seattle
Related Practices & Industries

Life Sciences Capital Markets Public Companies